Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder.

Trial Profile

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Guanfacine (Primary) ; Methylphenidate (Primary)
  • Indications Asperger syndrome; Autistic disorder; Hyperactivity; Pervasive child development disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2015 Treatment arm changed from 3 to 2 with removal of methylphenidate from the regimen as reported by ClinicalTrial.gov.
    • 29 Oct 2012 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 02 May 2012 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top